Zostavax Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to aging population demographics, rising incidence of shingles among older adults, established national immunization recommendations, availability of live attenuated vaccine platforms, expansion of hospital vaccination programs.

The growth in the forecast period can be attributed to shift toward recombinant and next-generation vaccines, increasing healthcare expenditure on preventive care, rising public awareness of postherpetic neuralgia risks, expansion of adult vaccination coverage, improved distribution infrastructure. Major trends in the forecast period include increasing focus on adult immunization programs, rising awareness of shingles prevention, expansion of vaccine access through retail pharmacies, improved cold chain and storage practices, growing emphasis on preventive healthcare.

The expansion of healthcare infrastructure in developing countries is expected to drive the growth of the Zostavax market. Healthcare infrastructure encompasses the facilities, equipment, personnel, and systems necessary to deliver effective healthcare services. Expansion in developing countries is largely fueled by increased investments in medical facilities and improved access to healthcare. This supports Zostavax by providing the necessary channels - such as clinics, hospitals, and pharmacies - for vaccine administration to the target population. For example, in May 2023, according to the Department of Health and Social Care, a UK-based government department, the New Hospital Programme received over $25.33 billion (£20 billion) in investment to build 40 new hospitals in England by 2030, including mental health facilities, with multiple hospitals already completed or under construction. Therefore, the expansion of healthcare infrastructure in developing countries is driving the growth of the Zostavax market.

Increasing insurance coverage is also expected to propel the Zostavax market. Insurance coverage provides financial protection against medical expenses, and its growth is driven by rising awareness of health risks, increasing healthcare costs, and demand for financial security against chronic and acute conditions. Zostavax benefits from broader insurance coverage as it serves as a preventative vaccine against shingles, reducing the risk of expensive treatments and long-term complications. For instance, in June 2024, according to Health Affairs, a US-based nonprofit organization, approximately 92.3% of the U.S. population (around 316 million people) had health coverage, while 7.7% (about 26 million people) remained uninsured. The insured population’s access supports uptake of preventative vaccines like Zostavax. Therefore, increasing insurance coverage is driving the growth of the Zostavax market.

The rising geriatric population is another factor supporting Zostavax market growth. The geriatric population, typically aged 65 and older, is expanding globally due to advancements in healthcare, improved living conditions, and better disease management, resulting in longer life expectancy. Zostavax is particularly important for older adults, as aging weakens the immune system and increases susceptibility to shingles and related complications. For example, in July 2024, according to the UK Parliament’s House of Commons Library, there were 12.7 million people aged 65 or older in the UK in 2022, representing 19% of the population; this number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growth of the geriatric population is driving the Zostavax market.

Major companies operating in the zostavax market are Merck & Co. Inc.

North America was the largest region in the zostavax market in 2025. The regions covered in the zostavax market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zostavax market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the zostavax market by increasing costs associated with imported biological raw materials, vaccine packaging components, cold-chain equipment, and specialized manufacturing inputs. North America and Europe are most affected due to reliance on cross-border sourcing for biologics production and distribution, while Asia-Pacific faces higher logistics and storage-related costs. These tariffs are contributing to increased pricing pressure for healthcare providers and vaccination programs. However, they are also encouraging localized vaccine manufacturing, regional supply chain diversification, and long-term investments in domestic biologics production capabilities.

The zostavax market research report is one of a series of new reports that provides zostavax market statistics, including zostavax industry global market size, regional shares, competitors with a zostavax market share, detailed zostavax market segments, market trends and opportunities, and any further data you may need to thrive in the zostavax industry. This zostavax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zostavax is a vaccine developed to prevent shingles, a painful rash caused by the reactivation of the varicella-zoster virus, which also causes chickenpox. It is primarily recommended for adults aged 50 and older to reduce the risk of shingles and related complications, such as postherpetic neuralgia.

The main formulations of Zostavax include recombinant vaccines (Shingrix) and live attenuated vaccines (Zostavax). Recombinant vaccines are produced using genetic engineering to generate an antigen that stimulates an immune response without using a live virus. Zostavax is used for the prevention of shingles and postherpetic neuralgia and is distributed through hospitals and retail pharmacies.

The zostavax market consists of sales of flu vaccines, pneumococcal vaccines hepatitis vaccines and meningitis vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.